[go: up one dir, main page]

NO20063064L - Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte - Google Patents

Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte

Info

Publication number
NO20063064L
NO20063064L NO20063064A NO20063064A NO20063064L NO 20063064 L NO20063064 L NO 20063064L NO 20063064 A NO20063064 A NO 20063064A NO 20063064 A NO20063064 A NO 20063064A NO 20063064 L NO20063064 L NO 20063064L
Authority
NO
Norway
Prior art keywords
treatment
central
peptide compounds
new use
neurotic pain
Prior art date
Application number
NO20063064A
Other languages
English (en)
Inventor
Thomas Stohr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03027742A external-priority patent/EP1537862A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20063064L publication Critical patent/NO20063064L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av peptidforbindelser for behandling av sentralnevropatisk smerte.
NO20063064A 2003-12-02 2006-06-30 Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte NO20063064L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03027742A EP1537862A1 (en) 2003-12-02 2003-12-02 Novel use of peptide compounds for treating central neuropathic pain
US53089503P 2003-12-22 2003-12-22
EP03029632 2003-12-22
PCT/EP2004/013729 WO2005053667A1 (en) 2003-12-02 2004-12-02 Novel use of peptide compounds for treating central neuropathic pain

Publications (1)

Publication Number Publication Date
NO20063064L true NO20063064L (no) 2006-09-01

Family

ID=34657533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063064A NO20063064L (no) 2003-12-02 2006-06-30 Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte

Country Status (16)

Country Link
US (1) US7794987B2 (no)
EP (1) EP1689378B1 (no)
JP (1) JP4664924B2 (no)
KR (1) KR20060111524A (no)
AT (1) ATE428413T1 (no)
AU (1) AU2004294714B2 (no)
BR (1) BRPI0417101A (no)
CA (1) CA2545543A1 (no)
DE (1) DE602004020657D1 (no)
EA (1) EA013590B1 (no)
ES (1) ES2325995T3 (no)
IL (1) IL175770A0 (no)
NO (1) NO20063064L (no)
NZ (1) NZ546576A (no)
PL (1) PL1689378T3 (no)
WO (1) WO2005053667A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
PL1689378T3 (pl) 2003-12-02 2009-09-30 Sanol Arznei Schwarz Gmbh Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
CN1950101B (zh) * 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
WO2006021412A2 (en) * 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
WO2007141018A1 (en) * 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
SI2462990T1 (sl) 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
WO2008070994A1 (en) 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
EP2214657A1 (en) * 2007-10-23 2010-08-11 UCB Pharma GmbH Compounds for treating demyelination conditions
RU2498995C2 (ru) * 2008-04-02 2013-11-20 Санофи-Авентис Пептиды с большим числом мостиковых связей, выделяемые из actinomadura namibiensis
WO2012072256A2 (en) 2010-12-02 2012-06-07 Ucb Pharma Gmbh Once daily formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
KR20210115502A (ko) 2020-03-13 2021-09-27 (주)포에버엔케이 기능성 펩타이드를 함유하는 경피 통증 경감 주사액 조성물
KR102884658B1 (ko) 2021-09-19 2025-11-11 (주)포에버엔케이 기능성 펩타이드를 함유하는 경피 통증 경감 주사액 조성물

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
IL87250A (en) 1987-08-01 1993-06-10 Takeda Chemical Industries Ltd :-unsaturated amines, process for their preparation, insecticidal/ miticidal compositions containing them
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
YU47834B (sr) 1989-08-10 1996-01-09 Schering Agrochemical Limited Azolni pesticid
TW217417B (no) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (en) * 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
ES2200184T7 (es) 1996-07-24 2015-02-10 Warner-Lambert Company Llc Isobutilgaba y sus derivados para el tratamiento del dolor
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6048899A (en) 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
WO1999002146A1 (en) 1997-07-08 1999-01-21 Ono Pharmaceutical Co., Ltd. Amino acid derivatives
AU744899B2 (en) 1997-07-15 2002-03-07 Research Corporation Technologies, Inc. Amino acid derivatives useful to treat stroke
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9816228D0 (en) 1998-07-24 1998-09-23 Pfizer Ltd Isoquinolines
DK1119256T3 (da) 1998-10-09 2003-09-29 Novartis Ag Oral kombination af lufenuron og nitenpyram mod lopper
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
HUP0201402A3 (en) 1999-09-03 2003-12-29 Actelion Pharmaceuticals Ltd Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
CA2348847A1 (en) 2000-05-31 2001-11-30 Pfizer Inc. New isoxazole-sulfonamide endothelin antagonists
SI1311256T1 (sl) 2000-08-17 2005-12-31 Teva Pharma Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
ES2435000T3 (es) * 2000-08-25 2013-12-18 Research Corporation Technologies, Inc. Aminoácidos anticonvulsionantes para el tratamiento del dolor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60134337D1 (de) 2000-11-21 2008-07-17 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
CA2434495A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
MXPA03008639A (es) 2001-03-27 2005-03-07 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolinas.
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
BR0316191A (pt) 2002-11-11 2005-09-27 Bayer Healthcare Ag Derivados de amino alcano de fenila ou heteroarila como antagonistas de receptor de ip
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040209960A1 (en) 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
US20040213842A1 (en) 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
EP1678121A4 (en) 2003-10-24 2007-07-25 Exelixis Inc MODULATORS OF TAO KINASES AND METHODS OF USE
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
PL1689378T3 (pl) 2003-12-02 2009-09-30 Sanol Arznei Schwarz Gmbh Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CN1950101B (zh) 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006021412A2 (en) 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia

Also Published As

Publication number Publication date
EP1689378B1 (en) 2009-04-15
ATE428413T1 (de) 2009-05-15
KR20060111524A (ko) 2006-10-27
BRPI0417101A (pt) 2007-02-06
AU2004294714A1 (en) 2005-06-16
EA013590B1 (ru) 2010-06-30
CA2545543A1 (en) 2005-06-16
NZ546576A (en) 2009-05-31
IL175770A0 (en) 2006-09-05
HK1095749A1 (zh) 2007-05-18
DE602004020657D1 (de) 2009-05-28
US20050209163A1 (en) 2005-09-22
WO2005053667A1 (en) 2005-06-16
JP2007513119A (ja) 2007-05-24
EA200601074A1 (ru) 2006-10-27
AU2004294714B2 (en) 2009-12-10
EP1689378A1 (en) 2006-08-16
US7794987B2 (en) 2010-09-14
JP4664924B2 (ja) 2011-04-06
PL1689378T3 (pl) 2009-09-30
ES2325995T3 (es) 2009-09-28

Similar Documents

Publication Publication Date Title
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EA200702455A1 (ru) Модуляторы индоламин 2,3-диоксигеназы и способы их применения
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
TW200626068A (en) Active compounds for seed treatment
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602007007618D1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EA202190888A1 (ru) Пептид для применения в косметике
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
NO20055741L (no) Nye kjemiske forbindelser
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
SE0002739D0 (sv) New use
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
DE10293089D2 (de) Phosphinat-peptidanaloga als Inhibitoren der Procollagen-C-Proteinase (PCP) zur Behandlung von fibrotischen Erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application